Conditions: Hepatitis C Virus Infection Chronic Hepatitis C Compensated Cirrhosis
Keywords: HCV Genotype 1 HCV Genotype 4 HCV Genotype 2 Cirrhotic Interferon-Free Compensated Cirrhosis HCV Genotype 5 Hepatitis C HCV Genotype 6
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 146
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.

Detailed description:

Arms:
arm 1: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Interventions: intervention 1: ABT-493/ABT-530
Intervention descriptions: intervention 1: Tablet; ABT-493 coformulated with ABT-530

Protocol document: